Learn and prepare
Everything for patients here is educational: plain-language answers, real numbers, and a private decision aid to prepare for a conversation with your surgical team. Nothing on this site recommends a choice for you.
Ovarian cancer prevention in Michigan
This discovery has changed what prevention can look like. If you are already having abdominal or pelvic surgery, your surgeon may be able to remove both Fallopian tubes during the same operation - and cut your risk of the most aggressive ovarian cancers at least in half.
The Fallopian tubes are two thin passageways, each a few inches long, that connect the ovaries to the uterus. After an ovary releases an egg, the egg travels through a Fallopian tube toward the uterus. The tubes do not make hormones - that is the ovaries’ job.
For nearly two decades, research has shown that most high-grade serous ovarian cancers - the most common and most aggressive kind - do not actually start in the ovaries. They start at the open end of a Fallopian tube and spread to the ovary from there. And because there is no reliable screening test for ovarian cancer, it is usually found late, after it has spread.
Removing both Fallopian tubes takes away the place where most of these cancers begin. Research estimates it cuts the risk at least in half - from about 11 in 1,000 to about 5 in 1,000 for an average-risk woman. The ovaries stay in place and keep making hormones, so tube removal has not been shown to change hormone levels or bring on earlier menopause.
If you are already scheduled for abdominal or pelvic surgery - an appendix, bowel, or gynecologic operation, for example - your surgeon may be able to remove both Fallopian tubes during that same operation. It usually adds less than 15 minutes. One thing to know before anything else: it is permanent, and pregnancy is no longer possible afterward without in vitro fertilization. The choice is always yours.
Out of 1,000 average-risk women, about 11 develop ovarian cancer during their lifetime. Research estimates that removing both Fallopian tubes lowers that to about 5 in 1,000.
Removal does not eliminate all ovarian cancer risk. After both Fallopian tubes are removed, pregnancy is no longer possible without in vitro fertilization. The choice is always yours - the decision aid helps you think it through and does not recommend an option.
Average lifetime risk of ovarian cancer
Research estimate after both Fallopian tubes are removed
For patients, this website is educational. The program itself works with Michigan providers to make the option available safely and consistently.
Everything for patients here is educational: plain-language answers, real numbers, and a private decision aid to prepare for a conversation with your surgical team. Nothing on this site recommends a choice for you.
MI-MAGIC's core work is with providers: training Michigan surgeons to counsel patients and add opportunistic salpingectomy safely, with implementation support and statewide measurement through MSQC.

In partnership with
Outsmart Ovarian CancerOutsmart Ovarian Cancer is a national education initiative from the American Cancer Society and Break Through Cancer, built on the same science: preventing ovarian cancer by removing the Fallopian tubes, where it starts. MI-MAGIC brings that message to Michigan operating rooms. Their site offers fact sheets, videos, guidelines, and news for patients and clinicians.
Every number on this site comes from a named study. These three anchor the program.
of women who developed high-grade serous ovarian cancer had an earlier abdominal or pelvic surgery where both Fallopian tubes could have been removed.
Tischer et al., Gynecologic Oncology, 2025 - 605 patientspassed, on average, between that earlier surgery and the cancer diagnosis. Prevention during surgery reaches women decades before the disease appears.
Tischer et al., Gynecologic Oncology, 2025 - median 30.0 yearsopportunistic salpingectomies prevent one ovarian cancer over a 20 to 30 year horizon - in the same range as screening colonoscopy for colorectal cancer.
Wright et al., Annals of Surgery, 2025; NordICC trial, NEJM, 2022MI-MAGIC (Michigan Multi-Specialty Action for Gynecologic Innovation & Care) is a University of Michigan program supported by the Canary Foundation and a University of Michigan Frankel Award. It works with the Michigan Surgical Quality Collaborative and its 70 member hospitals to train surgeons, support hospitals, and measure results statewide.
Summaries of the key studies behind the program, with sources named.
A validated tool for estimating personal risk and discussing prevention options.
Connections to gynecology, genetic counseling, and other prevention services.
Short educational videos and an Ask the Surgeon series.
Spanish and additional Michigan-relevant languages, added after review.